LRR1: A Protein with Potential as A Drug Target and Biomarker

Target Name: LRR1

NCBI ID: G122769

LRR1

LRR1: A Protein with Potential as A Drug Target and Biomarker

LRR1 (Leucine rich repeat protein 1, transcript variant 1) is a protein that is expressed in a variety of tissues throughout the body, including muscle, bone, and the brain. It is characterized by a unique repeat sequence, known as a leucine rich repeat, which is a type of protein domain that is found in many proteins and is involved in their structure and function.

Recent studies have suggested that LRR1 may have a variety of functions, including being involved in muscle growth and repair, bone development and density, and the regulation of inflammation. It has also been shown to be involved in the development and progression of certain diseases, such as cancer.

Due to these potential drug-target and biomarker properties, LRR1 has attracted a great deal of interest from researchers and pharmaceutical companies. Many studies have been conducted to investigate the effects of LRR1 on various cellular and biological processes, and several potential drug candidates have been identified.

One of the most promising LRR1-based drug targets is its role in the regulation of muscle growth and repair. LRR1 has been shown to play a role in the regulation of muscle protein synthesis and degradation, as well as in the maintenance of muscle mass and function. Several studies have shown that LRR1 deficiency can lead to muscle weakness and atrophy, and that administration of LRR1 can reverse these effects.

Another potential drug target for LRR1 is its role in bone development and density. LRR1 has been shown to be involved in the regulation of bone formation and maintenance, as well as in the regulation of bone resorption. Several studies have shown that LRR1 plays a critical role in the development and maintenance of strong bones, and that defects in LRR1 gene function have been linked to bone loss and fractures.

In addition to its potential drug-target properties, LRR1 has also been shown to be involved in the regulation of inflammation. LRR1 has been shown to play a role in the regulation of immune cell function, as well as in the regulation of inflammatory responses. Several studies have shown that LRR1 deficiency can increase the risk of certain inflammatory diseases, such as cancer and rheumatoid arthritis.

Overall, LRR1 is a protein that has a great deal of potential as a drug target and biomarker. Its unique repetitive sequences and various functions make it an attractive target for research into the regulation of muscle growth and repair, bone development and density, and inflammation . Further studies are needed to fully understand the role of LRR1 in these processes and to identify potential drug candidates.

Protein Name: Leucine Rich Repeat Protein 1

Functions: Substrate recognition subunit of an ECS (Elongin BC-CUL2/5-SOCS-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins (PubMed:15601820). ECS(LRR1) ubiquitinates MCM7 and promotes CMG replisome disassembly by VCP and chromatin extraction during S-phase (By similarity). May negatively regulate the 4-1BB-mediated signaling cascades which result in the activation of NK-kappaB and JNK1 (PubMed:11804328)

The "LRR1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LRR1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets